Who founded Good Therapeutics?

Good Therapeutics was founded by John Mulligan in 2016.

Who are Good Therapeutics's investors?

Good Therapeutics's investors include Digitalis Ventures, RiverVest Venture Partners, Roche Venture Fund.

How much funding has Good Therapeutics raised?

Good Therapeutics has disclosed $31.1M raised across 2 rounds.

Who acquired Good Therapeutics?

Good Therapeutics was acquired by Roche.

Where is Good Therapeutics headquartered?

Good Therapeutics is headquartered in Seattle, US.

Good Therapeutics

acquired by Roche

Seattle, US · Founded 2016 · Delaware corporation · 3 known investors

Portfolio company acquired by Roche.

Biotech

Founders & leadership

Good Therapeutics was founded in 2016 by John Mulligan.

John MulliganFounder

Mitchell MutzNamed on SEC filing

Nicholas WalrodNamed on SEC filing

Board

John McKearn in 𝕏Board directorSenior Advisor at RiverVest Venture Partners, focused on early-stage biotech

Karl HandelsmanBoard director

Investors · 3

Digitalis VenturesNew York · $100K – $10M

RiverVest Venture PartnersSt. Louis · $500K – $3M

Roche Venture FundreportedBasel · $648K – $3.2M

Reported raises · per SEC filings

Form D private placements

$31.1M disclosed across 2 rounds · 2018–2021

▶$8.8MraisedDec 2021 · 5 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Karl HandelsmanDirector
John MulliganExecutive Officer, Director, Promoter
Nicholas WalrodDirector
John McKearnDirector
Diane HollenbaughExecutive Officer
Monique SchiersingDirector
Neela PatelExecutive Officer

Offering amount: $26.4M
Amount sold: $8.8M
First sale: Dec 2021
Incorporated: Corporation, Delaware, 2016
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$22.3MraisedMay 2020 · 6 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Mitchell MutzDirector
John McKearnDirector
Nicholas WalrodDirector
John MulliganExecutive Officer, Director, Promoter
Karl HandelsmanDirector

Offering amount: $22.3M
Amount sold: $22.3M
First sale: Nov 2018
Incorporated: Corporation, Delaware, 2016
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Seattle biotech startup born out of a Roche buyout lands $93M to advance therapies – GeekWiregeekwire.com · Nov 2022

After $250M Roche buyout, a startup plans a second strike with fresh funding | BioPharma Divebiopharmadive.com · Nov 2022

Roche to pay $250M for Good Therapeutics and its targeted drug technology | BioPharma Divebiopharmadive.com · Sep 2022

Roche to acquire Good Therapeutics' lead drug program for $250M, plus milestone payments – GeekWiregeekwire.com · Sep 2022

Seattle Washington based Good Therapeutics is raising $22,335,003.00 in New Equity Investment. - intelligence360intelligence360.news · Jun 2020

Good Therapeutics raises $11M to develop 'context dependent' protein drugs – GeekWiregeekwire.com · May 2020

Frequently asked questions

What does Good Therapeutics do?: Portfolio company acquired by Roche.
Who founded Good Therapeutics?: Good Therapeutics was founded by John Mulligan in 2016.
Who are Good Therapeutics's investors?: Good Therapeutics's investors include Digitalis Ventures, RiverVest Venture Partners, Roche Venture Fund.
How much funding has Good Therapeutics raised?: Good Therapeutics has disclosed $31.1M raised across 2 rounds.
Who acquired Good Therapeutics?: Good Therapeutics was acquired by Roche.
Where is Good Therapeutics headquartered?: Good Therapeutics is headquartered in Seattle, US.